EFALIZUMAB Side Effects

6259310-8 |
on Jul 01, 2009 Male patient from UNITED STATES , weighting 250.4 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). . Efalizumab dosage: 2 Mg, Unk.

6255508-3 | Progressive Multifocal Leukoencephalopathy
Patient was taking Efalizumab (View Usage). Patient had the following side effects: progressive multifocal leukoencephalopathy on Jun 23, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 213.4 lb, was diagnosed with psoriasis, cardiovascular disorder, hyperlipidaemia, prophylaxis and. Efalizumab dosage: 1 Mg/kg, 1/week. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ), CLOPIDOGREL (75 Mg, Qd) (View Clopidogrel Review and Clopidogrel Label ), LEXAPRO (10 Mg, Qd) (View Lexapro Review and Lexapro Label ). Patient was hospitalized and became disabled.

6216560-4 | Hypergammaglobulinaemia Benign Monoclonal
Adverse event was reported on May 26, 2009 by a Female patient taking Efalizumab (View Usage) (Dosage: 0.86 Unk, 1/week) was diagnosed with psoriasis, hypertension, hypothyroidism, hypercholesterolaemia and. Location: UNITED STATES , weighting 188.1 lb, After Efalizumab was administered, patient had the following side effects: hypergammaglobulinaemia benign monoclonal. During the same period patient was treated with DIOVAN (80 Mg, Qd) (View Diovan Review and Diovan Label ), LEVOTHYROXINE (125 Mg, Qd) (View Levothyroxine Review and Levothyroxine Label ), SIMVASTATIN (80 Mg, Qd) (View Simvastatin Review and Simvastatin Label ), TACLONEX OINTMENT (Unk) (View Taclonex Ointment Review and Taclonex Ointment Label ), DOVONEX (Unk) (View Dovonex Review and Dovonex Label ), PROTOPIC (Unk) (View Protopic Review and Protopic Label ), CRESTOR (10 Mg, Qd) (View Crestor Review and Crestor Label ).

6200421-0 | Progressive Multifocal Leukoencephalopathy
on May 13, 2009 Male patient from UNITED STATES , weighting 213.4 lb, was diagnosed with psoriasis, cardiovascular disorder, hyperlipidaemia and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. Efalizumab dosage: 1 Mg/kg, 1/week. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ), CLOPIDOGREL (View Clopidogrel Review and Clopidogrel Label ). Patient was hospitalized and became disabled.


6192117-9 | Hypergammaglobulinaemia Benign Monoclonal
on May 05, 2009 Female patient from UNITED STATES , weighting 188.1 lb, was diagnosed with psoriasis, hypertension, hypothyroidism, hypercholesterolaemia and was treated with Efalizumab (View Usage). Patient had the following side effects: hypergammaglobulinaemia benign monoclonal. Efalizumab dosage: 0.86 Unk, 1/week. During the same period patient was treated with DIOVAN (80 Mg, Qd) (View Diovan Review and Diovan Label ), LEVOTHYROXINE SODIUM (125 Mg, Qd) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), SIMVASTATIN (80 Mg, Qd) (View Simvastatin Review and Simvastatin Label ), TACLONEX OINTMENT (Unk) (View Taclonex Ointment Review and Taclonex Ointment Label ), DOVONEX (Unk) (View Dovonex Review and Dovonex Label ), PROTOPIC (Unk) (View Protopic Review and Protopic Label ), CRESTOR (10 Mg, Qd) (View Crestor Review and Crestor Label ).

6176602-1 | Seborrhoeic Keratosis
Patient was taking Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: seborrhoeic keratosis on Apr 24, 2009 from AUSTRALIA Additional patient health information: Male patient , 56 years of age, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg/kg, 1/week.

6169146-4 | Amnesia, Confusional State, Disturbance In Attention, Dyspraxia, Neologism, Nuclear Magnetic Resonance Imaging Brain Abnormal, Thinking Abnormal
Adverse event was reported on Apr 17, 2009 by a Female patient taking Efalizumab (View Usage) (Dosage: 1 Mg, 1/week) was diagnosed with psoriasis and. Location: UNITED STATES , weighting 215.0 lb, Patient experienced the following unwanted or unexpected effects: amnesia, confusional state, disturbance in attention, dyspraxia, neologism, nuclear magnetic resonance imaging brain abnormal, thinking abnormal.

6157334-2 | Amnesia
on Apr 06, 2009 Female patient from UNITED STATES , weighting 215.0 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient had the following side effects: amnesia. Efalizumab dosage: 1 Mg, 1/week.

6135279-1 | Coagulopathy, Hepatitis B
on Mar 23, 2009 Male patient from SWITZERLAND , 66 years of age, was diagnosed with erythrodermic psoriasis and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: coagulopathy, hepatitis b (What is hepatitis b?). Efalizumab dosage: Unk. During the same period patient was treated with ADALIMUMAB (Unk) (View Adalimumab Review and Adalimumab Label ).

6119776-0 | Hepatitis B
Patient was taking Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: hepatitis b (What is hepatitis b?) on Mar 05, 2009 from GERMANY Additional patient health information: Male patient , 66 years of age, was diagnosed with erythrodermic psoriasis and. Efalizumab dosage: Unk. During the same period patient was treated with ADALIMUMAB (Unk) (View Adalimumab Review and Adalimumab Label ).

6094634-9 | Anaemia, Bladder Cancer, Malaise, Polyarthritis, Pyrexia, Vitamin B12 Deficiency, Weight Decreased
Adverse event was reported on Feb 20, 2009 by a Male patient taking Efalizumab (View Usage) (Dosage: 0.7 Mg/kg, Single) was diagnosed with psoriasis and. Location: SWITZERLAND , weighting 143.3 lb, Patient had the following side effects: anaemia, bladder cancer (What is bladder cancer?), malaise, polyarthritis, pyrexia, vitamin b12 deficiency, weight decreased. During the same period patient was treated with DURAGESIC 100 (75 Mg, Q3d) (View Duragesic-100 Review and Duragesic-100 Label ), PANTOZOL (40 Mg, Qd) (View Pantozol Review and Pantozol Label ), OXPRENOLOL (160 Mg, Qd) (View Oxprenolol Review and Oxprenolol Label ), IRBESARTAN (300 Mg, Qd) (View Irbesartan Review and Irbesartan Label ), LORAZEPAM (1 Mg, Tid) (View Lorazepam Review and Lorazepam Label ), ACENOCOUMAROL (1 Mg, Qd) (View Acenocoumarol Review and Acenocoumarol Label ). Patient was hospitalized.

6054417-2 | Progressive Multifocal Leukoencephalopathy
on Jan 16, 2009 Male patient from UNITED STATES , weighting 213.4 lb, was diagnosed with psoriasis, cardiovascular disorder, hyperlipidaemia and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. Efalizumab dosage: 1 Mg/kg, 1/week. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ), CLOPIDOGREL (View Clopidogrel Review and Clopidogrel Label ). Patient was hospitalized and became disabled.

6033524-4 | Myocardial Infarction
on Oct 13, 2008 Male patient from UNITED STATES , weighting 188.1 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: myocardial infarction. Efalizumab dosage: 0.8 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Prn) (View Topical Steroid Nos Review and Topical Steroid Nos Label ).

5957148-X | Cerebral Haemorrhage, Encephalitis
Patient was taking Efalizumab (View Usage). Patient had the following side effects: cerebral haemorrhage, encephalitis (What is encephalitis?) on Jul 25, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 210.5 lb, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with CALCIPOTRIENE (Unk, Prn) (View Calcipotriene Review and Calcipotriene Label ), COAL TAR PREPARATION (Unk, Prn) (View Coal Tar Preparation Review and Coal Tar Preparation Label ), STEROIDS (UNK INGREDIENTS) (Unk, Bid) (View Steroids (unk Ingredients) Review and Steroids (unk Ingredients) Label ), STEROID (UNK INGREDIENTS) (Unk, Bid) (View Steroid (unk Ingredients) Review and Steroid (unk Ingredients) Label ), ENBREL (50 Mg, 2/week) (View Enbrel Review and Enbrel Label ), RIFAMPIN (600 Mg, Qd) (View Rifampin Review and Rifampin Label ), ETHAMBUTOL HYDROCHLORIDE (1600 Mg, Qd) (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), ISONIAZID (900 Mg, Qd) (View Isoniazid Review and Isoniazid Label ). Patient was hospitalized.

5925988-9 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Oct 09, 2008 by a Male patient taking Efalizumab (View Usage) (Dosage: 90 Mg, 1/week) was diagnosed with psoriasis, hyperlipidaemia and. Location: UNITED STATES , weighting 213.4 lb, After Efalizumab was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ). Patient was hospitalized and became disabled.

5922789-2 | Back Pain, Chest Pain
on Oct 15, 2008 Male patient from CANADA , 39 years of age, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), chest pain (What is chest pain?). Efalizumab dosage: . During the same period patient was treated with BETADERM (CANADA) (Unk) (View Betaderm (canada) Review and Betaderm (canada) Label ), DOVONEX (Unk) (View Dovonex Review and Dovonex Label ), ARISTOCORT (Unk) (View Aristocort Review and Aristocort Label ), BETAMETHASONE DIPROPIONATE LOTION (Unk) (View Betamethasone Dipropionate Lotion Review and Betamethasone Dipropionate Lotion Label ).

5921574-5 | Lymphoma, Metastases To Liver
on Oct 16, 2008 Male patient from UNITED STATES , weighting 230.0 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient had the following side effects: lymphoma (What is lymphoma?), metastases to liver. Efalizumab dosage: 1.1 Ml Weekly Sub Q.

5916990-1 | Hypergammaglobulinaemia Benign Monoclonal
Patient was taking Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: hypergammaglobulinaemia benign monoclonal on Oct 01, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 188.1 lb, was diagnosed with psoriasis, hypertension, hypothyroidism, hypercholesterolaemia and. Efalizumab dosage: 0.86 Unk, 1/week. During the same period patient was treated with DIOVAN (80 Mg, Qd) (View Diovan Review and Diovan Label ), LEVOTHYROXINE SODIUM (125 Mg, Qd) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), SIMVASTATIN (80 Mg, Qd) (View Simvastatin Review and Simvastatin Label ), TACLONEX OINTMENT (Unk) (View Taclonex Ointment Review and Taclonex Ointment Label ), DOVONEX (Unk) (View Dovonex Review and Dovonex Label ), PROTOPIC (Unk) (View Protopic Review and Protopic Label ).

5916975-5 | Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Oct 08, 2008 by a Male patient taking Efalizumab (View Usage) (Dosage: Unk, 1/week) was diagnosed with psoriasis, hyperlipidaemia and. Location: UNITED STATES , weighting 206.1 lb, Patient experienced the following unwanted or unexpected effects: progressive multifocal leukoencephalopathy. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ). Patient was hospitalized.

5905706-0 | Progressive Multifocal Leukoencephalopathy
on Sep 22, 2008 Male patient from UNITED STATES , weighting 206.1 lb, was diagnosed with psoriasis, hyperlipidaemia and was treated with Efalizumab (View Usage). Patient had the following side effects: progressive multifocal leukoencephalopathy. Efalizumab dosage: Unk, 1/week. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), PRAVACHOL (View Pravachol Review and Pravachol Label ). Patient was hospitalized.

5905143-9 | Lupus-like Syndrome
on Sep 19, 2008 Male patient from UNITED STATES , weighting 178.8 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: lupus-like syndrome. Efalizumab dosage: 1 Mg, Qow. During the same period patient was treated with TOPICAL STEROID (UNK INGREDIENTS) (Unk) (View Topical Steroid (unk Ingredients) Review and Topical Steroid (unk Ingredients) Label ), DERMA SMOOTHE/FS (Unk) (View Derma-smoothe/fs Review and Derma-smoothe/fs Label ), LUXIQ (Unk) (View Luxiq Review and Luxiq Label ).

5868987-8 | Bladder Cancer, Malaise, Pyrexia
Patient was taking Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: bladder cancer (What is bladder cancer?), malaise, pyrexia on Aug 29, 2008 from SWITZERLAND Additional patient health information: Male patient , weighting 143.3 lb, was diagnosed with psoriasis and. Efalizumab dosage: 0.7 Mg/kg, Single. During the same period patient was treated with DURAGESIC 100 (75 Mg, Q3d) (View Duragesic-100 Review and Duragesic-100 Label ), PANTOZOL (40 Mg, Qd) (View Pantozol Review and Pantozol Label ), OXPRENOLOL (160 Mg, Qd) (View Oxprenolol Review and Oxprenolol Label ), IRBESARTAN (300 Mg, Qd) (View Irbesartan Review and Irbesartan Label ), LORAZEPAM (1 Mg, Tid) (View Lorazepam Review and Lorazepam Label ), ACENOCOUMAROL (1 Mg, Qd) (View Acenocoumarol Review and Acenocoumarol Label ). Patient was hospitalized.

5850237-X | Bladder Cancer, Malaise, Pyrexia
Adverse event was reported on Aug 15, 2008 by a Male patient taking Efalizumab (View Usage) (Dosage: 0.7 Mg/kg, Single) was diagnosed with psoriasis and. Location: SWITZERLAND , weighting 143.3 lb, Patient had the following side effects: bladder cancer (What is bladder cancer?), malaise, pyrexia. During the same period patient was treated with DURAGESIC 100 (75 Mg, Q3d) (View Duragesic-100 Review and Duragesic-100 Label ), PANTOZOL (40 Mg, Qd) (View Pantozol Review and Pantozol Label ), OXPRENOLOL (160 Mg, Qd) (View Oxprenolol Review and Oxprenolol Label ), IRBESARTAN (300 Mg, Qd) (View Irbesartan Review and Irbesartan Label ), LORAZEPAM (1 Mg, Tid) (View Lorazepam Review and Lorazepam Label ), ACENOCOUMAROL (1 Mg, Qd) (View Acenocoumarol Review and Acenocoumarol Label ). Patient was hospitalized.

5845319-2 | Herpes Zoster Disseminated, Nausea
on Aug 13, 2008 Male patient from UNITED STATES , weighting 154.3 lb, was diagnosed with renal transplant, immunosuppression and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: herpes zoster disseminated, nausea (What is nausea?). Efalizumab dosage: 70 Mg, 1/week. During the same period patient was treated with PRAVASTATIN (20 Mg, Qhs) (View Pravastatin Review and Pravastatin Label ), CELLCEPT (Unk) (View Cellcept Review and Cellcept Label ), PREDNISONE TAB (5 Mg, Qd) (View Prednisone Tab Review and Prednisone Tab Label ), PEPCID (Unk) (View Pepcid Review and Pepcid Label ), LOPRESSOR (50 Mg, Bid) (View Lopressor Review and Lopressor Label ), PROCARDIA (Unk) (View Procardia Review and Procardia Label ). Patient was hospitalized.

5845258-7 | Encephalitis, Lacunar Infarction, Urosepsis
on Aug 11, 2008 Male patient from UNITED STATES , weighting 145.5 lb, was diagnosed with renal transplant, prophylaxis and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: encephalitis (What is encephalitis?), lacunar infarction, urosepsis. Efalizumab dosage: 76 Mg, 1/week. During the same period patient was treated with CELLCEPT (Unk) (View Cellcept Review and Cellcept Label ), PREDNISONE TAB (Unk) (View Prednisone Tab Review and Prednisone Tab Label ), PEPCID (Unk) (View Pepcid Review and Pepcid Label ), LOPRESSOR (Unk) (View Lopressor Review and Lopressor Label ), MAG OX (Unk) (View Mag-ox Review and Mag-ox Label ), NPH ILETIN II (Unk) (View Nph Iletin Ii Review and Nph Iletin Ii Label ), GLYBURIDE (Unk) (View Glyburide Review and Glyburide Label ), PRAVASTATIN (Unk) (View Pravastatin Review and Pravastatin Label ). Patient was hospitalized.

5828830-X | Pancytopenia
Patient was taking Efalizumab (View Usage). Patient had the following side effects: pancytopenia on Jul 24, 2008 from FRANCE Additional patient health information: Male patient , 47 years of age, was diagnosed with psoriasis and. Efalizumab dosage: .

5816823-8 | Cerebral Haemorrhage
Adverse event was reported on Jul 09, 2008 by a Male patient taking Efalizumab (View Usage) (Dosage: 1 Mg, 1/week) was diagnosed with psoriasis and. Location: UNITED STATES , weighting 210.5 lb, After Efalizumab was administered, patient had the following side effects: cerebral haemorrhage. During the same period patient was treated with CALCIPOTRIENE (Unk, Prn) (View Calcipotriene Review and Calcipotriene Label ), COAL TAR PREPARATION (Unk, Prn) (View Coal Tar Preparation Review and Coal Tar Preparation Label ), STEROIDS (UNK INGREDIENTS) (Unk, Bid) (View Steroids (unk Ingredients) Review and Steroids (unk Ingredients) Label ), STEROID (UNK INGREDIENTS) (Unk, Bid) (View Steroid (unk Ingredients) Review and Steroid (unk Ingredients) Label ), ENBREL (50 Mg, 2/week) (View Enbrel Review and Enbrel Label ). Patient was hospitalized.

5815505-6 | Molluscum Contagiosum
on Jul 10, 2008 Female patient from GREECE , 29 years of age, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: molluscum contagiosum. Efalizumab dosage: . During the same period patient was treated with REMICADE (5 Mg/kg, Unk) (View Remicade Review and Remicade Label ).

5815503-2 | Papilloma Viral Infection
on Jul 10, 2008 Female patient from GREECE , 29 years of age, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient had the following side effects: papilloma viral infection. Efalizumab dosage: . During the same period patient was treated with REMICADE (5 Mg/kg, Unk) (View Remicade Review and Remicade Label ).

5806979-5 |
Patient was taking Efalizumab (View Usage). on Jul 01, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 210.5 lb, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with CALCIPOTRIENE (Unk, Prn) (View Calcipotriene Review and Calcipotriene Label ), COAL TAR PREPARATION (Unk, Prn) (View Coal Tar Preparation Review and Coal Tar Preparation Label ), STEROIDS (UNK INGREDIENTS) (Unk, Bid) (View Steroids (unk Ingredients) Review and Steroids (unk Ingredients) Label ), STEROID (UNK INGREDIENTS) (Unk, Bid) (View Steroid (unk Ingredients) Review and Steroid (unk Ingredients) Label ), ENBREL (50 Mg, 2/week) (View Enbrel Review and Enbrel Label ). Patient was hospitalized.

5735500-5 | Fibrous Histiocytoma
Adverse event was reported on May 06, 2008 by a Female patient taking Efalizumab (View Usage) (Dosage: 1 Mg/kg, 1/week) was diagnosed with psoriasis and. Location: SWITZERLAND , 44 years of age, Patient experienced the following unwanted or unexpected effects: fibrous histiocytoma.

5728871-7 | Cardiac Failure Congestive
on Apr 28, 2008 Female patient from UNITED STATES , weighting 185.0 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient had the following side effects: cardiac failure congestive. Efalizumab dosage: 1 Mg, 1/week. Patient was hospitalized and became disabled.

5655785-3 | Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Creatinine Increased, Bone Marrow Disorder, Candidiasis, Diarrhoea, Enterococcal Infection, Headache, Iron Deficiency Anaemia
on Feb 25, 2008 Female patient from UNITED STATES , weighting 158.7 lb, was diagnosed with psoriasis, gastrooesophageal reflux disease, depression (What is depression?), medical diet, chronic sinusitis and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood creatinine increased, bone marrow disorder, candidiasis, diarrhoea, enterococcal infection, headache (What is headache?), iron deficiency anaemia. Efalizumab dosage: 1 Mg/kg, 1/week. During the same period patient was treated with NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), WELLBUTRIN XL (150 Mg, Qd) (View Wellbutrin Xl Review and Wellbutrin Xl Label ), VITAMIN E (400 Iu, Qd) (View Vitamin E Review and Vitamin E Label ), CENTRUM SILVER (Unk, Qd) (View Centrum Silver Review and Centrum Silver Label ), DOVONEX (Unk, Qd) (View Dovonex Review and Dovonex Label ), BIAXIN XL (500 Mg, Bid) (View Biaxin Xl Review and Biaxin Xl Label ), FLONASE (50 G, Bid) (View Flonase Review and Flonase Label ). Patient was hospitalized and became disabled.

5635480-7 | Malignant Fibrous Histiocytoma
Patient was taking Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: malignant fibrous histiocytoma on Feb 12, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 128.1 lb, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg, 1/week. Patient was hospitalized.

5628277-5 | Appendicitis
Adverse event was reported on Feb 11, 2008 by a Female patient taking Efalizumab (View Usage) (Dosage: ) was diagnosed with psoriasis and. Location: UNITED STATES , 46 years of age, Patient had the following side effects: appendicitis (What is appendicitis?). Patient was hospitalized and became disabled.

5612303-3 |
on Jan 29, 2008 Male patient from UNITED STATES , weighting 210.5 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). . Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with CALCIPOTRIENE (Unk, Prn) (View Calcipotriene Review and Calcipotriene Label ), COAL TAR PREPARATION (Unk, Prn) (View Coal Tar Preparation Review and Coal Tar Preparation Label ), STEROIDS (UNK INGREDIENTS) (Unk, Bid) (View Steroids (unk Ingredients) Review and Steroids (unk Ingredients) Label ), STEROID (UNK INGREDIENTS) (Unk, Bid) (View Steroid (unk Ingredients) Review and Steroid (unk Ingredients) Label ), ENBREL (50 Mg, 2/week) (View Enbrel Review and Enbrel Label ). Patient was hospitalized.

5611689-3 | Appendicitis
on Jan 22, 2008 Female patient from UNITED STATES , 46 years of age, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: appendicitis (What is appendicitis?). Efalizumab dosage: . Patient was hospitalized.

5588302-7 | Cardiac Failure Congestive
Patient was taking Efalizumab (View Usage). Patient had the following side effects: cardiac failure congestive on Jan 02, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 83.89 lb, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg, 1/week. Patient was hospitalized and became disabled.

5584599-8 | Breast Cancer, Pyrexia
Adverse event was reported on Dec 20, 2007 by a Female patient taking Efalizumab (View Usage) (Dosage: 0.7 Mg/k/w, X2) was diagnosed with sweat gland infection and. Location: UNITED STATES , 38 years of age, After Efalizumab was administered, patient had the following side effects: breast cancer (What is breast cancer?), pyrexia.

5584174-5 | Lung Neoplasm, Respiratory Tract Infection Bacterial
on Jan 02, 2008 Female patient from UNITED STATES , 38 years of age, was diagnosed with graft versus host disease and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: lung neoplasm, respiratory tract infection bacterial. Efalizumab dosage: . Patient was hospitalized.

5571960-0 | Deep Vein Thrombosis
on Dec 10, 2007 Female patient from UNITED STATES , weighting 175.4 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). Patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?). Efalizumab dosage: 1 Mg, Unk.

5567127-2 |
Patient was taking Efalizumab (View Usage). on Sep 27, 2007 from UNITED STATES Additional patient health information: Male patient , weighting 188.1 lb, was diagnosed with psoriasis and. Efalizumab dosage: 0.8 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Prn) (View Topical Steroid Nos Review and Topical Steroid Nos Label ).

5523647-8 | Syncope
Adverse event was reported on Nov 14, 2007 by a Female patient taking Efalizumab (View Usage) (Dosage: 1 Mg, 1/week) was diagnosed with psoriasis, anaemia, nausea (What is nausea?), back pain (What is back pain?), gastrooesophageal reflux disease, depression (What is depression?) and. Location: UNITED STATES , weighting 190.4 lb, Patient experienced the following unwanted or unexpected effects: syncope. During the same period patient was treated with METHOTREXATE (2.5 Mg, Unk) (View Methotrexate Review and Methotrexate Label ), FOLIC ACID (1 Mg, Unk) (View Folic Acid Review and Folic Acid Label ), METOCLOPRAMIDE (10 Mg, Prn) (View Metoclopramide Review and Metoclopramide Label ), MORPHINE SULFATE (60 Mg, Tid) (View Morphine Sulfate Review and Morphine Sulfate Label ), OMEPRAZOLE (20 Mg, Qd) (View Omeprazole Review and Omeprazole Label ), TRAZODONE HCL (300 Mg, Unk) (View Trazodone Hcl Review and Trazodone Hcl Label ), EFFEXOR XR (300 Mg, Qam) (View Effexor Xr Review and Effexor Xr Label ). Patient was hospitalized and became disabled.

5512118-0 | Pulmonary Embolism
on Oct 29, 2007 Female patient from UNITED STATES , weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome (What is irritable bowel syndrome?) and was treated with Efalizumab (View Usage). Patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Qd) (View Topical Steroid Nos Review and Topical Steroid Nos Label ), DYAZIDE (1 Tablet, Qd) (View Dyazide Review and Dyazide Label ), CALCIUM (500 Mg, Tid) (View Calcium Review and Calcium Label ), ALLEGRA D 24 HOUR (1 Tablet, Qd) (View Allegra D 24 Hour Review and Allegra D 24 Hour Label ), BENTYL (1 Tablet, Qd) (View Bentyl Review and Bentyl Label ). Patient was hospitalized.

5511695-3 | Pneumonia Fungal
on Oct 29, 2007 Female patient from UNITED STATES , weighting 175.4 lb, was diagnosed with psoriasis and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: pneumonia fungal. Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with STEROIDS NOS (Unk, Qd) (View Steroids Nos Review and Steroids Nos Label ). Patient was hospitalized.

5501970-0 | Pneumonia Fungal
Patient was taking Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia fungal on Oct 16, 2007 from UNITED STATES Additional patient health information: Female patient , weighting 175.4 lb, was diagnosed with psoriasis and. Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with STEROIDS NOS (Unk, Qd) (View Steroids Nos Review and Steroids Nos Label ). Patient was hospitalized.

5501195-9 | Deep Vein Thrombosis
Adverse event was reported on Oct 17, 2007 by a Female patient taking Efalizumab (View Usage) (Dosage: 1 Mg, Unk) was diagnosed with psoriasis and. Location: UNITED STATES , weighting 175.4 lb, Patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?).

5490795-0 | Pulmonary Embolism
on Sep 04, 2007 Female patient from UNITED STATES , weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome (What is irritable bowel syndrome?) and was treated with Efalizumab (View Usage). After Efalizumab was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Qd) (View Topical Steroid Nos Review and Topical Steroid Nos Label ), DYAZIDE (1 Tablet, Qd) (View Dyazide Review and Dyazide Label ), CALCIUM (500 Mg, Tid) (View Calcium Review and Calcium Label ), ALLEGRA D 24 HOUR (1 Tablet, Qd) (View Allegra D 24 Hour Review and Allegra D 24 Hour Label ), BENTYL (1 Tablet, Qd) (View Bentyl Review and Bentyl Label ). Patient was hospitalized.

5486009-8 | Pulmonary Embolism
on Sep 04, 2007 Female patient from UNITED STATES , weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome (What is irritable bowel syndrome?) and was treated with Efalizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?). Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Qd) (View Topical Steroid Nos Review and Topical Steroid Nos Label ), DYAZIDE (1 Tablet, Qd) (View Dyazide Review and Dyazide Label ), CALCIUM (500 Mg, Tid) (View Calcium Review and Calcium Label ), ALLEGRA D 24 HOUR (1 Tablet, Qd) (View Allegra D 24 Hour Review and Allegra D 24 Hour Label ), BENTYL (1 Tablet, Qd) (View Bentyl Review and Bentyl Label ). Patient was hospitalized.

5472076-4 | Pulmonary Embolism
Patient was taking Efalizumab (View Usage). Patient had the following side effects: pulmonary embolism (What is pulmonary embolism?) on Sep 04, 2007 from UNITED STATES Additional patient health information: Female patient , weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome (What is irritable bowel syndrome?) and. Efalizumab dosage: 1 Mg, 1/week. During the same period patient was treated with TOPICAL STEROID NOS (Unk, Qd) (View Topical Steroid Nos Review and Topical Steroid Nos Label ), DYAZIDE (1 Tablet, Qd) (View Dyazide Review and Dyazide Label ), CALCIUM (500 Mg, Tid) (View Calcium Review and Calcium Label ), ALLEGRA D 24 HOUR (1 Tablet, Qd) (View Allegra D 24 Hour Review and Allegra D 24 Hour Label ), BENTYL (1 Tablet, Qd) (View Bentyl Review and Bentyl Label ). Patient was hospitalized.